Our Services
Medical Information
Helpful Resources
Published on: 11/9/2026
Biphasic anaphylaxis is a second surge of systemic allergic symptoms that strikes after the first reaction appears fully resolved, most often 4 to 12 hours later but possibly up to 72 hours, and it happens because injected epinephrine wears off in roughly 10 to 20 minutes while late-phase inflammatory cells, newly synthesized mediators, and residual allergen in the gut or tissues keep driving mast cell and basophil activation. Known risk factors include delayed or insufficient epinephrine, needing more than one dose, severe or hypotensive initial symptoms, an unknown trigger, and oral or food-based exposures, which is why observation periods and a second auto-injector matter. Important nuances about warning signs, monitoring windows, and when the rebound is more likely to be severe are covered below, so review the complete answer rather than this summary alone.
Because a returning wave of hives, throat tightness, vomiting, wheezing, or lightheadedness can escalate quickly and is easy to mistake for anxiety or a lingering first reaction, getting a fast read on your symptoms helps you decide whether to use epinephrine again and call emergency services now. Take a free, instant, online symptom check to clarify what your current symptoms may indicate and what step to take next.
Last reviewed for medical accuracy: 11/09/2026
Biphasic anaphylaxis is a second episode of anaphylaxis that develops after the first episode has improved or completely resolved, without a new exposure to the original trigger. It can occur several hours after treatment, including after an initial dose of epinephrine appeared to work.
This delayed reaction is uncommon, but it is medically important. Anyone with possible anaphylaxis should receive urgent medical assessment, even if symptoms improve after epinephrine.
Anaphylaxis is a rapid, whole-body allergic or hypersensitivity reaction. It can affect the skin, breathing, heart and blood circulation, stomach and intestines, and nervous system.
During a reaction, immune cells such as mast cells and basophils release powerful chemical mediators, including histamine, tryptase, leukotrienes, and prostaglandins. These substances can cause:
Epinephrine is the first-line treatment for anaphylaxis because it rapidly supports blood pressure, relaxes airway muscles, reduces swelling, and helps limit the release of additional inflammatory mediators. However, epinephrine does not remain active in the body for a long time. Its effects may wear off while the underlying immune response is still active.
In biphasic anaphylaxis, the initial symptoms improve after treatment, but similar or new symptoms return later. The second phase occurs without another clear exposure to the allergen.
The second episode may be milder than the first, but it can also be serious. It may involve breathing problems, low blood pressure, or swelling of the airway. A person should not assume that a second wave is “just anxiety,” indigestion, or a side effect of epinephrine.
Research and clinical guidelines report different rates because studies use different definitions and follow-up periods. Modern evidence suggests that biphasic reactions occur in a minority of anaphylaxis cases—often estimated at roughly 5% or less—but the risk is higher after severe or poorly controlled reactions. Most delayed reactions happen within several hours, although later recurrence has been reported.
The exact biological mechanism is not fully understood. A biphasic reaction is probably not caused by one single process. Several explanations may contribute.
Epinephrine can quickly reverse the effects of anaphylaxis, but it may not completely stop mast cells and basophils from releasing mediators. The immune response can continue at a lower level and then become clinically noticeable again after the initial improvement.
This is one reason a person may feel better temporarily and then develop swelling, wheezing, hives, vomiting, or dizziness later.
Some allergens are absorbed gradually, particularly food allergens. Digestion and continued absorption from the gastrointestinal tract may expose the immune system to more of the trigger over time.
In other situations, a medication may remain in the bloodstream or tissues, or an insect sting may continue to cause local absorption of venom. This does not necessarily mean a new exposure occurred. It may reflect continued exposure from the original event.
A delayed or inadequate initial dose of epinephrine can allow the reaction to progress before treatment takes effect. Severe anaphylaxis may also require repeated doses, intravenous fluids, oxygen, or other hospital-based treatment.
If the first episode was only temporarily suppressed, symptoms may return as the effect of epinephrine decreases. This is sometimes described as “rebound,” but it is not usually a withdrawal reaction to epinephrine. It more likely reflects ongoing or reactivated anaphylaxis.
Anaphylaxis involves complex interactions among immune cells, blood vessels, airway tissues, and inflammatory chemicals. The early phase may cause sudden symptoms, while later inflammatory signaling contributes to renewed symptoms.
This proposed “two-phase” process is one reason biphasic reactions can occur even when the original trigger is no longer entering the body. However, the precise mechanism remains an area of medical research.
No one can predict with certainty who will develop biphasic anaphylaxis. Clinical guidance from organizations such as the World Allergy Organization, the American Academy of Allergy, Asthma & Immunology, and the Resuscitation Council UK identifies several features associated with greater risk:
These are risk factors, not predictions. A mild-looking first reaction can occasionally worsen, and a severe reaction does not always become biphasic.
A return of breathing, circulation, throat, or whole-body symptoms after an initial improvement should be treated as a medical emergency.
If anaphylaxis is suspected:
Anyone who has used epinephrine for suspected anaphylaxis should be medically evaluated. Symptoms can recur, and observation time should be individualized according to the severity of the reaction, treatment required, and risk factors. There is no single observation period that completely guarantees a biphasic reaction will not occur.
Current evidence does not support the idea that epinephrine causes biphasic anaphylaxis. Epinephrine is the recommended first-line treatment and can be lifesaving. Temporary effects such as shaking, rapid heartbeat, headache, pallor, or anxiety are common after epinephrine and usually wear off.
Those effects are different from renewed anaphylaxis. Trouble breathing, throat swelling, faintness, persistent vomiting, widespread hives with other symptoms, or signs of poor circulation require urgent medical attention.
After recovery, a doctor or allergy specialist can help identify possible triggers, review how the reaction was treated, prescribe or renew epinephrine auto-injectors, and create a written emergency plan. Testing may be appropriate, but it should be arranged by a qualified clinician rather than performed during the acute emergency.
For general symptom guidance, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It cannot diagnose anaphylaxis or replace emergency care. If anything could be life-threatening or serious—or if you are unsure—speak to a doctor or contact emergency services immediately.
Medical basis: This explanation reflects guidance and evidence from the World Allergy Organization anaphylaxis guidance, the Resuscitation Council UK emergency guidelines, American allergy and immunology practice guidance, and systematic reviews of biphasic anaphylaxis.
(References)
* Reingardiene D. [The consequence of epinephrine (adrenaline) overdose]. Medicina (Kaunas). 2006;42(7):606-9. PMID: 16861845.
* Shaker MS, Wallace DV, Golden DBK, Oppenheimer J, Bernstein JA, Campbell RL, Dinakar C, Ellis A, Greenhawt M, Khan DA, Lang DM, Lang ES, Lieberman JA, Portnoy J, Rank MA, Stukus DR, Wang J, Collaborators, Riblet N, Bobrownicki AMP, Bontrager T, Dusin J, Foley J, Frederick B, Fregene E, Hellerstedt S, Hassan F, Hess K, Horner C, Huntington K, Kasireddy P, Keeler D, Kim B, Lieberman P, Lindhorst E, McEnany F, Milbank J, Murphy H, Pando O, Patel AK, Ratliff N, Rhodes R, Robertson K, Scott H, Snell A, Sullivan R, Trivedi V, Wickham A, Chief Editors, Shaker MS, Wallace DV, Workgroup Contributors, Shaker MS, Wallace DV, Bernstein JA, Campbell RL, Dinakar C, Ellis A, Golden DBK, Greenhawt M, Lieberman JA, Rank MA, Stukus DR, Wang J, Joint Task Force on Practice Parameters Reviewers, Shaker MS, Wallace DV, Golden DBK, Bernstein JA, Dinakar C, Ellis A, Greenhawt M, Horner C, Khan DA, Lieberman JA, Oppenheimer J, Rank MA, Shaker MS, Stukus DR, Wang J. Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol. 2020 Apr;145(4):1082-1123. doi: 10.1016/j.jaci.2020.01.017. Epub 2020 Jan 28. PMID: 32001253.
* Pflipsen MC, Vega Colon KM. Anaphylaxis: Recognition and Management. Am Fam Physician. 2020 Sep 15;102(6):355-362. PMID: 32931210.
* Tanno LK, Demoly P. Anaphylaxis in children. Pediatr Allergy Immunol. 2020 Nov;31 Suppl 26:8-10. doi: 10.1111/pai.13336. PMID: 33236416.
* McHugh K, Repanshek Z. Anaphylaxis: Emergency Department Treatment. Emerg Med Clin North Am. 2022 Feb;40(1):19-32. doi: 10.1016/j.emc.2021.08.004. Epub 2021 Oct 29. PMID: 34782088.
* Motosue MS, Li JT, Campbell RL. Anaphylaxis: Epidemiology and Differential Diagnosis. Immunol Allergy Clin North Am. 2022 Feb;42(1):13-25. doi: 10.1016/j.iac.2021.09.010. PMID: 34823743.
* Navalpakam A, Thanaputkaiporn N, Poowuttikul P. Management of Anaphylaxis. Immunol Allergy Clin North Am. 2022 Feb;42(1):65-76. doi: 10.1016/j.iac.2021.09.005. PMID: 34823751.
* McHugh K, Repanshek Z. Anaphylaxis: Emergency Department Treatment. Immunol Allergy Clin North Am. 2023 Aug;43(3):453-466. doi: 10.1016/j.iac.2022.10.002. PMID: 37394252.
* Dribin TE, Muraro A, Camargo CA Jr, Turner PJ, Wang J, Roberts G, Anagnostou A, Halken S, Liebermann J, Worm M, Zuberbier T, Sampson HA, GA(2)LEN Anaphylaxis Study Team. Anaphylaxis definition, overview, and clinical support tool: 2024 consensus report-a GA(2)LEN project. J Allergy Clin Immunol. 2025 Aug;156(2):406-417.e6. doi: 10.1016/j.jaci.2025.01.021. Epub 2025 Jan 27. PMID: 39880313; PMCID: PMC12301991.
* Wallace DV, Hossny EM, Levin M, Munblit D, Turner PJ. Anaphylaxis Guidelines. Immunol Allergy Clin North Am. 2026 May;46(2):233-256. doi: 10.1016/j.iac.2026.01.007. Epub 2026 Mar 4. PMID: 41932745.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.